Use access key #2 to skip to page content.
$11.96 0.53 (4.64%)
10/7/2008 11:22 AM

Momenta Pharmaceuticals, Inc. (MNTA)

CAPS Rating:
****

A biotechnology company specializing in the detailed structural analysis of complex mixture drugs of the development of generic or biosimilar versions of complex drug products as well as to the discovery and development of novel drugs.

View Ticker Page (MNTA)

Results 31 - 40 of 45 :   12345

Recs

0

Avatar thorwest (89.44) Submitted: 11/10/06 11:26 PM : Outperform Start Price: $15.63 MNTA Score: -0.01

Their pipeline is growing and there entry into generic drugs requires less time to market. Their technology into sequencing sugars makes this a one of a kind company.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

Avatar ToogleBH (42.28) Submitted: 11/26/06 1:11 AM : Outperform Start Price: $17.34 MNTA Score: -6.43

Biotech. Developing several generic drugs that have proven difficult to reproduce.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

Avatar Ausbeginner (80.85) Submitted: 10/31/07 8:32 PM : Outperform Start Price: $17.38 MNTA Score: -6.11

extending this time frame out to 18months, several products in the pipeline waiting on FDA approval

Report this Post Replies: 0 | Reply | Permalink

Recs

0

Avatar darkstar13 (< 20) Submitted: 1/18/07 8:12 PM : Outperform Start Price: $17.48 MNTA Score: -5.75

Like they said in last month's Rule Breakers issue: "Potential 85$ stock"

Report this Post Replies: 0 | Reply | Permalink

Recs

0

Avatar TomFoolNC (24.11) Submitted: 2/11/07 2:59 PM : Outperform Start Price: $16.29 MNTA Score: -0.05

buying opp

Report this Post Replies: 0 | Reply | Permalink

Recs

0

Avatar touya (< 20) Submitted: 2/15/07 4:32 PM : Outperform Start Price: $13.73 MNTA Score: 14.35

Unjustifiably beaten down. Still believe in the story, so MNTA presents a good momentum to buy.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

Avatar lbrules (42.80) Submitted: 2/16/07 8:37 PM : Outperform Start Price: $13.23 MNTA Score: 17.69

The recent drop is a good buying opportunity. None of the fundementals have changed and there is the recent possibility of another generic drug to add to the bottom line.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

Avatar nvda (28.35) Submitted: 2/22/07 12:43 PM : Outperform Start Price: $13.01 MNTA Score: 19.25

Levonox patent is invalidated opening the door for generic version of drug for MNTA. Now the only hurdle is the FDA ruling approaching within the next two quarter. Stock sold off on good news, very good buying opportunity at around $13.00.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

Avatar RussFoolery (54.11) Submitted: 2/22/07 6:25 PM : Outperform Start Price: $12.88 MNTA Score: 20.23

good buy in at $13, we should know within a year if gets the rights to sell the generic versions of the drugs

Report this Post Replies: 0 | Reply | Permalink

Recs

0

Avatar oceansk8er (< 20) Submitted: 3/08/07 11:21 AM : Outperform Start Price: $11.49 MNTA Score: 28.85

Fool analysts are scratching their heads at why the stock fell off a cliff due to what should be viewed as positive news. I like biotech in the current overheated market environment (and especially biotech falling knives) because they won't sell off...

Report this Post Replies: 0 | Reply | Permalink

Featured Broker Partners